Use of intravenous immunoglobulin in multiple sclerosis

BioDrugs

Volumn 9, Issue 6, 1998, Pages 465-475

  Achiron, Anat ^a   Barak, Yoram ^b   Sarova Pinhas, Ida ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; COMPLEMENT; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHYLPREDNISOLONE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NONHUMAN; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REMYELINIZATION; REVIEW; SUPPRESSOR CELL;

EID: 0031861264     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809060-00004     Document Type: Review

References (58)

1. Bussell J, Hilgartner MW. Usage of intravenous gammaglobulins in the treatment of chronic idiopathic thrombocytopenic purpura. In: Morell A, Nydegger UE, editors. Clinical uses of intravenous immunoglobulins. Orlando (FL): Academic Press, 1986; 217-21
2. Zweiman B. Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis. Clin Immunol Immunopathol 1989; 53: 583-91
3. Sandor M, Gajewski T, Thorson J, et al. CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin-4-producing T helper cell type 2 subset. J Exp Med 1990; 171: 2171-6
4. Nyland H, Nilsen R. Localization of Fcγ receptors in the human central nervous system. Acta Path Microbiol Immunol Scand 1982; 90: 217-21
5. Ulvetad E, Williams K, Matre R, et al. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody coated targets. J Neuropathol Exp Neurol 1994; 53: 27-36
6. Morimoto C, Hafler DA, Weiner HL, et al. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. N Engl J Med 1987; 316: 67-72
7. Reinherz EL, Weiner HL, Hauser SL, et al. Loss of suppressor T cells in active multiple sclerosis. N Engl J Med 1980; 303: 125-9
8. Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180-6
9. Achiron A, Margalit R, Hershkoviz R, et al. Intravenous immunoglobulin treatment of experimental T-cell mediated autoimmune diseases: up-regulation of T cell proliferation and down-regulation of TNF-α secretion. J Clin Invest 1994; 93: 600-5
10. Acha-Orbea H, Mitchell DJ, Timmermann L, et al. Limited heterogeneity of T cell receptors from T lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988; 54: 263-73
11. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995; 37 (S1): S87-101
12. Sakai K, Zamvil SS, Mitchell DJ, et al. Prevention of experimental allergic encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci USA 1989; 86: 9470-4
13. Lamont G, Sette A, Fujinami R, et al. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IA molecules. J Immunol 1990; 145: 1687-93
14. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-33
15. Link J, Soderstrom, M, Olsson T, et al. Increased TGF-β, IL-4 and IFN-γ in multiple sclerosis. Ann Neurol 1994; 35: 197-203
16. Andersson U, Bjork L, Skansen-Saphir U, et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42
17. Abe Y, Horiuchi A, Miyake M, et al. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139: 5-19
18. Achiron A, Barak Y, Sarova-Pinhas I, et al. Intravenous immunoglobulins in relapsing-remitting multiple sclerosis. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulin research and therapy. New York: The Parthenon Publishing Group, 1996; 289-93
19. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46
20. Selmaj KW, Raine CS, Cannella B, et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87: 949-54
21. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-72
22. Hartung HP, Archelos JJ, Zielasek J, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 1995; 45 Suppl. 6: S22-S32
23. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992; 356: 63-6
24. Burdette S, Schwartz RS. Idiotypes and idiotypic networks. N Engl J Med 1987; 317: 219-24
25. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110: 135-49
26. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988; 25: 41-8
27. Seigneurin MJ, Guilbert B, Bourgeat MJ, et al. Polyspecific natural antibodies and autoantibodies secreted by human lymphocytes immortalized with Epstein-Barr virus. Blood 1988; 71: 581-5
28. Olsson T, Baig S, Hojeberg B, et al. Antimyelin basic protein and anti myelin-producing cells in multiple sclerosis. Ann Neurol 1990; 27: 132-6
29. Jans H, Heltberg A, Zeeberg I, et al. Immune complexes and the complement factor C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta Neurol Scand 1984; 69: 34-8
30. Basta M, Dalakas MC. High dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35
31. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 1994; 57 Suppl.: 21-35
32. Nyland H, Nilsen R. Localization of Fcγ receptors in the human central nervous system. Acta Path Microbiol Immunol Scand 1982; 90: 217-21
33. Ludwin SK. An autoradiographic study of cellular proliferation in remyelination of the central nervous system. Am J Pathol 1979; 95: 683-96
34. Arenella L, Herndon RM. Mature oligodendrocytes: division following experimental demyelination in adult animals. Arch Neurol 1984; 41: 1162-5
35. Baulac M, Lachapelle F, Gout O, et al. Transplantation of oligodendrocytes in the newborn mouse brain: extension of myelination by transplanted cells. Anatomical study. Brain Res 1987; 420: 39-47
36. Gansmuller A, Lachappele F, Baron-Van Evercooren A, et al. Transplantation of newborn CNS fragments into the brain of shiverer mutant mice: extensive myelination by transplanted oligodendrocytes. II. Electron microscopic study. Dev Neurosci 1986; 8: 197-207
37. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990; 27: 12-7
38. Rodriguez M. Immunoglobulins stimulate central nervous system remyelination: electron microscopic and morphometric analysis of proliferating cells. Lab Invest 1991; 64: 358-70
39. Achiron A, Barak Y, Goren M, et al. Intravenous immunoglobulin in multiple sclerosis: clinical and neuroradiologic results and implications for possible mechanisms of action. Clin Exp Immunol 1996; 104 Suppl. 1: 67-70
40. Sorensen P, Wanscher B, Jensen CV, et al. Intravenous immune globulin G reduces MR1 activity in multiple sclerosis. Eur J Neurol 1996; 3 Suppl. 4: 34
41. Rotherfelder U, Neu I, Pelka R. Therapy for multiple sclerosis with immunoglobulin G. MMW Munch Med Wochenschr 1982; 124: 74-8
42. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983; 22: 205-12
43. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experience with 7S immunoglobulins in MS therapy. Wien Med Wochenschr 1986; 136: 477-80
44. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of high-dose intravenous immunoglobulins in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-6
45. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52
46. Achiron A, Gilad R, Margalit R, et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune diseases: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994; 57 Suppl.: 57-61
47. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin in multiple sclerosis: a multicenter, double-blind, placebo-controlled trial. Neurology 1996; 46 Suppl.: A405-6
48. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-93
49. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998; 50: 398-402
50. Cook SD, Troiano R, Rohowsky-Kochin C, et al. Intravenous gamma globulin in progressive MS. Acta Neurol 1992; 86: 171-5
51. Poehlau D, Amoiridis G, Postert T, et al. Intravenous immunoglobulin (IVIg) for the treatment of progressive multiple sclerosis. J Neuroimmunol 1995; Suppl. 1: 47
52. Poehlau D, Amoiridis G, Postert T, et al. Results of double-blind randomised placebo-controlled pilot study on the treatment of multiple sclerosis with intravenous immunoglobulin. Eur J Neurol 1996; 3 Suppl. 4: 58
53. Noseworthy JH, Rodriguez M, An KN, et al. IVIG treatment in multiple sclerosis: pilot study results and design of placebo-controlled, double-blind clinical trial [abstract]. Ann Neurol 1994; 325: P266
54. van Engelen BG, Hommes OR, Pinckers A, et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992; 32: 834-5
55. Thompson AJ, Noseworthy JH. New treatments for multiple sclerosis: a clinical perspective. Curr Opin Neurol 1996; 9: 187-98
56. Achiron A, Rotstein Z, Noy S, et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25-8
57. Tankersley DL, Mason BL, Guo ZP, et al. Viral safety of intravenous immunoglobulin. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulin research and therapy New York: The Parthenon Publishing Group, 1996; 3-9
58. Brannagan TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 46: 674-7